{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:19:54Z","timestamp":1791652794989,"version":"4.3.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12325-025-03367-5","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T04:05:14Z","timestamp":1763438714000},"page":"49-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical and Real-World Evidence on Etanercept Biosimilar Switching: A Narrative Literature Review of Efficacy and Safety"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-2299","authenticated-orcid":false,"given":"Marc","family":"Schmalzing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-0493","authenticated-orcid":false,"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C. V.","family":"Perez-Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristofer","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bachinskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"3367_CR1","doi-asserted-by":"publisher","first-page":"1168972","DOI":"10.3389\/fphar.2023.1168972","volume":"14","author":"A Wajda","year":"2023","unstructured":"Wajda A, Perricone C, Kashyap A, Iliyasu MY. Editorial: Biological drugs and biosimilars in autoimmune diseases. Front Pharmacol. 2023;14:1168972. https:\/\/doi.org\/10.3389\/fphar.2023.1168972.","journal-title":"Front Pharmacol"},{"key":"3367_CR2","doi-asserted-by":"publisher","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.009.","journal-title":"Semin Arthritis Rheum"},{"key":"3367_CR3","unstructured":"European Medicines Agency. Biosimilars in the EU: information guide for healthcare professionals. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 15 May\u00a02023."},{"issue":"2","key":"3367_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/14737167.2023.2297926","volume":"24","author":"J Mestre-Ferrandiz","year":"2024","unstructured":"Mestre-Ferrandiz J, Czech M, Smolen JS, et al. Capturing the holistic value of biosimilars in Europe \u2013 part 1: a historical perspective. Expert Rev Pharmacoecon Outcomes Res. 2024;24(2):237\u201350. https:\/\/doi.org\/10.1080\/14737167.2023.2297926.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3367_CR5","unstructured":"European Medicines Agency. Enbrel summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enbrel-epar-product-information_en.pdf. Accessed 28 Feb 2025."},{"key":"3367_CR6","unstructured":"U.S. Food and Drug Administration. Enbrel prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103795s5600lbl.pdf. Accessed 28 Feb 2025."},{"key":"3367_CR7","unstructured":"GaBi. Biosimilars of etanercept. https:\/\/gabionline.net\/biosimilars\/general\/biosimilars-of-etanercept. Accessed 28 Feb 2025."},{"key":"3367_CR8","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Benepali. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-benepali_en.pdf. Accessed 28 Feb 2025."},{"key":"3367_CR9","unstructured":"European Medicines Agency. Benepali. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/benepali. Accessed 28 Feb 2025."},{"key":"3367_CR10","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Nepexto. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-nepexto_en.pdf. Accessed 28 Feb 2025."},{"key":"3367_CR11","unstructured":"European Medicines Agency. Nepexto. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nepexto. Accessed 28 Feb 2025."},{"key":"3367_CR12","doi-asserted-by":"publisher","first-page":"1151764","DOI":"10.3389\/fphar.2023.1151764","volume":"14","author":"E Car","year":"2023","unstructured":"Car E, Vulto AG, Houdenhoven MV, Huys I, Simoens S. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front Pharmacol. 2023;14:1151764. https:\/\/doi.org\/10.3389\/fphar.2023.1151764.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3367_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-020-00456-5","volume":"35","author":"E Moorkens","year":"2021","unstructured":"Moorkens E, Vulto AG, Kent J, et al. A look at the history of biosimilar adoption: characteristics of early and late adopters of infliximab and etanercept biosimilars in subregions of England, Scotland and Wales - a mixed methods study. BioDrugs. 2021;35(1):75\u201387. https:\/\/doi.org\/10.1007\/s40259-020-00456-5.","journal-title":"BioDrugs"},{"key":"3367_CR14","unstructured":"Novartis. US Supreme Court denies Sandoz petition to review biosimilar Erelzi\u00ae (etanercept-szzs) case. 2021. https:\/\/www.novartis.com\/news\/media-releases\/us-supreme-court-denies-sandoz-petition-review-biosimilar-erelzi-etanercept-szzs-case. Accessed 28 Feb 2025."},{"key":"3367_CR15","unstructured":"Statista. Median prices of Enbrel in selected countries in 2019. 2019. https:\/\/www.statista.com\/statistics\/312007\/price-of-enbrel-by-country\/. Accessed 17 Dec 2024."},{"issue":"4","key":"3367_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.therap.2021.10.012","volume":"77","author":"Q Jarrion","year":"2022","unstructured":"Jarrion Q, Azzouz B, Robinson J, Jolly D, Vallet C, Trenque T. Penetration rate of anti-TNF biosimilars and savings at 5\u00a0years after their introduction in French hospitals. Therapie. 2022;77(4):467\u201375. https:\/\/doi.org\/10.1016\/j.therap.2021.10.012.","journal-title":"Therapie"},{"issue":"9","key":"3367_CR17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/ard-2022-223696","volume":"82","author":"M Stajszczyk","year":"2023","unstructured":"Stajszczyk M, Obarska I, Jeka S, Batko B. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database. Ann Rheum Dis. 2023;82(9):1171\u201380. https:\/\/doi.org\/10.1136\/ard-2022-223696.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3367_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40259-017-0252-3","volume":"31","author":"MI Aladul","year":"2017","unstructured":"Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017;31(6):533\u201344. https:\/\/doi.org\/10.1007\/s40259-017-0252-3.","journal-title":"BioDrugs"},{"issue":"9","key":"3367_CR19","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/acr.25099","volume":"75","author":"AR McClean","year":"2023","unstructured":"McClean AR, Cheng L, Bansback N, et al. Uptake and spending on biosimilar infliximab and etanercept after new start and switching policies in Canada: an interrupted time series analysis. Arthritis Care Res (Hoboken). 2023;75(9):2011\u201321. https:\/\/doi.org\/10.1002\/acr.25099.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"3367_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/acr2.11106","volume":"2","author":"N Bansback","year":"2020","unstructured":"Bansback N, Curtis JR, Huang J, et al. Patterns of tumor necrosis factor inhibitor (TNFi) biosimilar use across United States rheumatology practices. ACR Open Rheumatol. 2020;2(2):79\u201383. https:\/\/doi.org\/10.1002\/acr2.11106.","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"3367_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40259-024-00659-0","volume":"38","author":"C Rieger","year":"2024","unstructured":"Rieger C, Dean JA, Hall L, Vasquez P, Merlo G. Barriers and enablers affecting the uptake of biosimilar medicines viewed through the lens of actor network theory: a systematic review. BioDrugs. 2024;38(4):541\u201355. https:\/\/doi.org\/10.1007\/s40259-024-00659-0.","journal-title":"BioDrugs"},{"issue":"8","key":"3367_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.18553\/jmcp.2019.18412","volume":"25","author":"L Greene","year":"2019","unstructured":"Greene L, Singh RM, Carden MJ, Pardo CO, Lichtenstein GR. Strategies for overcoming barriers to adopting biosimilars and achieving goals of the biologics price competition and innovation act: a survey of managed care and specialty pharmacy professionals. J Manag Care Spec Pharm. 2019;25(8):904\u201312. https:\/\/doi.org\/10.18553\/jmcp.2019.18412.","journal-title":"J Manag Care Spec Pharm"},{"key":"3367_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01372","volume":"10","author":"L Colloca","year":"2019","unstructured":"Colloca L, Panaccione R, Murphy TK. The clinical implications of nocebo effects for biosimilar therapy. Front Pharmacol. 2019;10:1372. https:\/\/doi.org\/10.3389\/fphar.2019.01372.","journal-title":"Front Pharmacol"},{"issue":"12","key":"3367_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190147","volume":"12","author":"E Moorkens","year":"2017","unstructured":"Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS ONE. 2017;12(12):e0190147. https:\/\/doi.org\/10.1371\/journal.pone.0190147.","journal-title":"PLoS ONE"},{"issue":"1","key":"3367_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1907-x","volume":"21","author":"J Jaworski","year":"2019","unstructured":"Jaworski J, Matucci-Cerinic M, Schulze-Koops H, et al. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase\u00a0III, randomized, double-blind EQUIRA study. Arthritis Res Ther. 2019;21(1):130. https:\/\/doi.org\/10.1186\/s13075-019-1907-x.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3367_CR26","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/bjd.15152","volume":"176","author":"CEM Griffiths","year":"2017","unstructured":"Griffiths CEM, Tha\u00e7i D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928\u201338. https:\/\/doi.org\/10.1111\/bjd.15152.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3367_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1910-2","volume":"21","author":"MC Park","year":"2019","unstructured":"Park MC, Matsuno H, Kim J, et al. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase\u00a0III multicentre, randomised, double-blind, parallel-group study. Arthritis Res Ther. 2019;21(1):122. https:\/\/doi.org\/10.1186\/s13075-019-1910-2.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"3367_CR28","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1136\/annrheumdis-2017-211591","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsk\u00fd J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017;76(12):1986\u201391. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211591.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3367_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12325-023-02706-8","volume":"41","author":"M Schmalzing","year":"2024","unstructured":"Schmalzing M, Kellner H, Askari A, et al. Real-world effectiveness and safety of SDZ ETN, an etanercept biosimilar, in patients with rheumatic diseases: final results from multi-country COMPACT study. Adv Ther. 2024;41(1):315\u201330. https:\/\/doi.org\/10.1007\/s12325-023-02706-8.","journal-title":"Adv Ther"},{"issue":"11","key":"3367_CR30","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1007\/s12325-022-02303-1","volume":"39","author":"J Pope","year":"2022","unstructured":"Pope J, Hall S, Bombardier C, et al. Post-switch effectiveness of etanercept biosimilar versus continued etanercept in rheumatoid arthritis patients with stable disease: a prospective multinational observational study. Adv Ther. 2022;39(11):5259\u201373. https:\/\/doi.org\/10.1007\/s12325-022-02303-1.","journal-title":"Adv Ther"},{"issue":"2","key":"3367_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/annrheumdis-2018-213474","volume":"78","author":"B Glintborg","year":"2019","unstructured":"Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78(2):192\u2013200. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213474.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3367_CR32","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/art.40516","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study. Arthritis Rheumatol. 2018;70(9):1408\u201318. https:\/\/doi.org\/10.1002\/art.40516.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"3367_CR33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/jcm11030621","volume":"11","author":"S Parisi","year":"2022","unstructured":"Parisi S, Becciolini A, Ditto MC, et al. Efficacy and drug survival after switching from etanercept to the biosimilar SB4: a real-life long-term study. J Clin Med. 2022;11(3):621. https:\/\/doi.org\/10.3390\/jcm11030621.","journal-title":"J Clin Med"},{"key":"3367_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x221119593","volume":"14","author":"U Kiltz","year":"2022","unstructured":"Kiltz U, Tsiami S, Baraliakos X, Andreica I, Kiefer D, Braun J. Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases. Ther Adv Musculoskelet Dis. 2022;14:1759720x221119593. https:\/\/doi.org\/10.1177\/1759720x221119593.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"6","key":"3367_CR35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/mr\/roae018","volume":"34","author":"T Kawakami","year":"2024","unstructured":"Kawakami T, Masui S, Onishi A, et al. Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort. Mod Rheumatol. 2024;34(6):1135\u201341. https:\/\/doi.org\/10.1093\/mr\/roae018.","journal-title":"Mod Rheumatol"},{"key":"3367_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x20964031","volume":"12","author":"C Bruni","year":"2020","unstructured":"Bruni C, Gentileschi S, Pacini G, et al. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Ther Adv Musculoskelet Dis. 2020;12:1759720x20964031. https:\/\/doi.org\/10.1177\/1759720x20964031.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"Suppl 1","key":"3367_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.31138\/mjr.30.1.69","volume":"30","author":"AV Madenidou","year":"2019","unstructured":"Madenidou AV, Jeffries A, Varughese S, et al. Switching patients with inflammatory arthritis from etanercept (Enbrel\u00ae) to the biosimilar drug, SB4 (Benepali\u00ae): a single-centre retrospective observational study in the UK and a review of the literature. Mediterr J Rheumatol. 2019;30(Suppl 1):69\u201375. https:\/\/doi.org\/10.31138\/mjr.30.1.69.","journal-title":"Mediterr J Rheumatol"},{"issue":"7","key":"3367_CR38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/09546634.2019.1606886","volume":"31","author":"C Bonifati","year":"2020","unstructured":"Bonifati C, De Felice C, Lora V, Morrone A, Graceffa D. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study. J Dermatolog Treat. 2020;31(7):687\u201391. https:\/\/doi.org\/10.1080\/09546634.2019.1606886.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"3367_CR39","doi-asserted-by":"publisher","first-page":"102255362412658","DOI":"10.1177\/10225536241265818","volume":"32","author":"H Sakane","year":"2024","unstructured":"Sakane H, Yonemoto Y, Okamura K, et al. Efficacy of switching from originator etanercept to biosimilar YLB113 in real-world patients with rheumatoid arthritis: a retrospective 12\u00a0months follow-up study. J Orthop Surg (Hong Kong). 2024;32(2):10225536241265818. https:\/\/doi.org\/10.1177\/10225536241265818.","journal-title":"J Orthop Surg (Hong Kong)"},{"issue":"9","key":"3367_CR40","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/acr.25345","volume":"76","author":"K \u0141osi\u0144ska","year":"2024","unstructured":"\u0141osi\u0144ska K, Pripp AH, Bakland G, et al. Comparative effectiveness and persistence of SB4 and reference etanercept in patients with psoriatic arthritis in Norway. Arthritis Care Res (Hoboken). 2024;76(9):1303\u201312. https:\/\/doi.org\/10.1002\/acr.25345.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3367_CR41","doi-asserted-by":"publisher","first-page":"16178","DOI":"10.1038\/s41598-020-73183-0","volume":"10","author":"MC Ditto","year":"2020","unstructured":"Ditto MC, Parisi S, Priora M, et al. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. Sci Rep. 2020;10(1):16178. https:\/\/doi.org\/10.1038\/s41598-020-73183-0.","journal-title":"Sci Rep"},{"issue":"4","key":"3367_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40259-021-00485-8","volume":"35","author":"S Piaserico","year":"2021","unstructured":"Piaserico S, Conti A, Messina F, et al. Cross-switch from etanercept originator to biosimilar SB4 and to GP2015 in patients with chronic plaque psoriasis. BioDrugs. 2021;35(4):469\u201371. https:\/\/doi.org\/10.1007\/s40259-021-00485-8.","journal-title":"BioDrugs"},{"key":"3367_CR43","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/ppa.S169339","volume":"12","author":"B Tischer","year":"2018","unstructured":"Tischer B, Mehl A. Patients\u2019 and nurses\u2019 preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Prefer Adherence. 2018;12:1413\u201324. https:\/\/doi.org\/10.2147\/ppa.S169339.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"3367_CR44","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1136\/annrheumdis-2018-214908","volume":"79","author":"M Scherlinger","year":"2020","unstructured":"Scherlinger M, Schaeverbeke T. \u201cTo switch or not to switch\u201d: the missing piece in the puzzle of biosimilar literature? Ann Rheum Dis. 2020;79(4):e36. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214908.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3367_CR45","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40259-021-00479-6","volume":"35","author":"AR Kolbe","year":"2021","unstructured":"Kolbe AR, Kearsley A, Merchant L, et al. Physician understanding and willingness to prescribe biosimilars: findings from a US national survey. BioDrugs. 2021;35(3):363\u201372. https:\/\/doi.org\/10.1007\/s40259-021-00479-6.","journal-title":"BioDrugs"},{"issue":"3","key":"3367_CR46","first-page":"185","volume":"22","author":"F Cantini","year":"2020","unstructured":"Cantini F, Niccoli L, Franchi G, Damiani A, Benucci M. The nocebo effect in rheumatology: an unexplored issue. Isr Med Assoc J. 2020;22(3):185\u201390.","journal-title":"Isr Med Assoc J"},{"issue":"1","key":"3367_CR47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.55563\/clinexprheumatol\/6cxcaq","volume":"43","author":"O Hagege","year":"2024","unstructured":"Hagege O, Brevet P, Gerard B, et al. Evaluation of the nocebo effect after switching from etanercept or adalimumab originator to a biosimilar: a retrospective study of patients with inflammatory rheumatism. Clin Exp Rheumatol. 2024;43(1):87\u201395. https:\/\/doi.org\/10.55563\/clinexprheumatol\/6cxcaq.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"3367_CR48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/mr\/road027","volume":"34","author":"T Matsubara","year":"2024","unstructured":"Matsubara T, Katayama K, Sagawa A, et al. Investigation of treatment continuity, usefulness, and nocebo effect in switching from the original etanercept to its biosimilar in patients with rheumatoid arthritis: a JET observational study in Japanese clinical practice. Mod Rheumatol. 2024;34(2):307\u201312. https:\/\/doi.org\/10.1093\/mr\/road027.","journal-title":"Mod Rheumatol"},{"issue":"8","key":"3367_CR49","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1093\/rheumatology\/kead470","volume":"63","author":"L Kearsley-Fleet","year":"2024","unstructured":"Kearsley-Fleet L, Rokad A, Tsoi MF, et al. Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA. Rheumatology (Oxford). 2024;63(8):2082\u201392. https:\/\/doi.org\/10.1093\/rheumatology\/kead470.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3367_CR50","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.55563\/clinexprheumatol\/mc1jhk","volume":"39","author":"U Kiltz","year":"2021","unstructured":"Kiltz U, Pudelko JC, Tsiami S, Baraliakos X, Braun J. Non-medical switching from reference to biosimilar etanercept - no evidence for nocebo effect: a retrospective analysis of real-life data. Clin Exp Rheumatol. 2021;39(6):1345\u201351. https:\/\/doi.org\/10.55563\/clinexprheumatol\/mc1jhk.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"3367_CR51","doi-asserted-by":"publisher","first-page":"952","DOI":"10.18553\/jmcp.2018.24.10.952","volume":"24","author":"JS Odinet","year":"2018","unstructured":"Odinet JS, Day CE, Cruz JL, Heindel GA. The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies. J Manag Care Spec Pharm. 2018;24(10):952\u20139. https:\/\/doi.org\/10.18553\/jmcp.2018.24.10.952.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"3367_CR52","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40290-024-00541-y","volume":"38","author":"E Car","year":"2024","unstructured":"Car E, Vandenplas Y, Lacosta TB, et al. Mitigating the nocebo effect in biosimilar use and switching: a systematic review. Pharmaceut Med. 2024;38(6):429\u201355. https:\/\/doi.org\/10.1007\/s40290-024-00541-y.","journal-title":"Pharmaceut Med"},{"issue":"10","key":"3367_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ph13100324","volume":"13","author":"E Moorkens","year":"2020","unstructured":"Moorkens E, Barcina Lacosta T, Vulto AG, et al. Learnings from regional market dynamics of originator and biosimilar infliximab and etanercept in Germany. Pharmaceuticals (Basel). 2020;13(10):324. https:\/\/doi.org\/10.3390\/ph13100324.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"3367_CR54","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/imj.14753","volume":"50","author":"T Kovitwanichkanont","year":"2020","unstructured":"Kovitwanichkanont T, Raghunath S, Wang D, et al. Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis. Intern Med J. 2020;50(3):374\u20137. https:\/\/doi.org\/10.1111\/imj.14753.","journal-title":"Intern Med J"},{"issue":"2","key":"3367_CR55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/ejhpharm-2019-001999","volume":"28","author":"CM Barbosa","year":"2021","unstructured":"Barbosa CM, Rodr\u00edguez de Castro B, Labeaga Beramendi Y, Terroba Alonso P, Barbaz\u00e1n V\u00e1zquez J. Patient satisfaction survey: substitution of reference etanercept with a biosimilar product. Eur J Hosp Pharm. 2021;28(2):109\u201311. https:\/\/doi.org\/10.1136\/ejhpharm-2019-001999.","journal-title":"Eur J Hosp Pharm"},{"issue":"2","key":"3367_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12020065","volume":"12","author":"DC Rosembert","year":"2024","unstructured":"Rosembert DC, Twigg MJ, Wright DJ. Patient\u2019s and consultant\u2019s views and perceptions on switching from an originator biologic to biosimilar medication: a qualitative study. Pharmacy (Basel). 2024;12(2):65. https:\/\/doi.org\/10.3390\/pharmacy12020065.","journal-title":"Pharmacy (Basel)"},{"issue":"2","key":"3367_CR57","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/rheumatology\/keaa502","volume":"60","author":"A Gibofsky","year":"2021","unstructured":"Gibofsky A, McCabe D. US rheumatologists\u2019 beliefs and knowledge about biosimilars: a survey. Rheumatology (Oxford). 2021;60(2):896\u2013901. https:\/\/doi.org\/10.1093\/rheumatology\/keaa502.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"3367_CR58","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40259-017-0238-1","volume":"31","author":"MI Aladul","year":"2017","unstructured":"Aladul MI, Fitzpatrick RW, Chapman SR. Patients\u2019 understanding and attitudes towards infliximab and etanercept biosimilars: result of a UK web-based survey. BioDrugs. 2017;31(5):439\u201346. https:\/\/doi.org\/10.1007\/s40259-017-0238-1.","journal-title":"BioDrugs"},{"issue":"3","key":"3367_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105322","volume":"89","author":"C Levivien","year":"2022","unstructured":"Levivien C, Bottois C, L\u00f3pez Medina C, et al. Impact of a clinical pharmacist in a multidisciplinary consultation on the switch to a biosimilar for inflammatory rheumatic diseases. Joint Bone Spine. 2022;89(3):105322. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105322.","journal-title":"Joint Bone Spine"},{"issue":"8","key":"3367_CR60","first-page":"469","volume":"6","author":"EA Blackstone","year":"2013","unstructured":"Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469\u201378.","journal-title":"Am Health Drug Benefits"},{"key":"3367_CR61","unstructured":"European Medicines Agency. Biosimilar medicines: overview. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/biosimilar-medicines-overview. Accessed 28 Feb 2025."},{"issue":"11","key":"3367_CR62","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.drudis.2020.09.006","volume":"25","author":"M-C Bielsky","year":"2020","unstructured":"Bielsky M-C, Cook A, Wallington A, et al. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov Today. 2020;25(11):1910\u20138. https:\/\/doi.org\/10.1016\/j.drudis.2020.09.006.","journal-title":"Drug Discov Today"},{"key":"3367_CR63","unstructured":"European Medicines Agency. Benepali summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benepali-epar-product-information_en.pdf. Accessed 28 Feb 2025."},{"key":"3367_CR64","unstructured":"European Medicines Agency. Erelzi summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/erelzi-epar-product-information_en.pdf. Accessed 28 Feb 2025."},{"issue":"1","key":"3367_CR65","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/1756-185x.14462","volume":"26","author":"H Yamanaka","year":"2023","unstructured":"Yamanaka H, Tanaka Y, Hibino T, et al. Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: results from a post-hoc analysis of a double-blind, randomized, phase\u00a0III comparative study and its open-label extension in patients with rheumatoid arthritis. Int J Rheum Dis. 2023;26(1):108\u201315. https:\/\/doi.org\/10.1111\/1756-185x.14462.","journal-title":"Int J Rheum Dis"},{"issue":"11","key":"3367_CR66","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1080\/13696998.2019.1652183","volume":"22","author":"M Tarallo","year":"2019","unstructured":"Tarallo M, Onishchenko K, Alexopoulos ST. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK. J Med Econ. 2019;22(11):1162\u201370. https:\/\/doi.org\/10.1080\/13696998.2019.1652183.","journal-title":"J Med Econ"},{"issue":"1","key":"3367_CR67","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41927-021-00235-x","volume":"6","author":"A Fisher","year":"2022","unstructured":"Fisher A, Kim JD, Carney G, Dormuth C. Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept \u2013 a cohort study in British Columbia. BMC Rheumatol. 2022;6(1):5. https:\/\/doi.org\/10.1186\/s41927-021-00235-x.","journal-title":"BMC Rheumatol"},{"issue":"6","key":"3367_CR68","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5114\/reum.2018.80710","volume":"56","author":"K Kowalik","year":"2018","unstructured":"Kowalik K, W\u0119gierska M, Barczy\u0144ska T, Jeka S. Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment. Reumatologia. 2018;56(6):340\u20135. https:\/\/doi.org\/10.5114\/reum.2018.80710.","journal-title":"Reumatologia"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03367-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03367-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03367-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:32:18Z","timestamp":1769765538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03367-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3367"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03367-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marc Schmalzing declares having received compensation for consulting from Chugai\/Roche, Hexal\/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer Ingelheim, onkowissen.de, EUSA-Pharma, Novartis, AstraZeneca, Amgen, Medac, Lilly and Galapagos; speaker\u2019s fees from Novartis, AbbVie, AstraZeneca, Chugai\/Roche, Janssen-Cilag, Gilead, Boehringer Ingelheim, Mylan, Galapagos and EUSA-Pharma; and travel grants from Chugai\/Roche, Boehringer Ingelheim, Celgene, Medac, UCB, Mylan and Galapagos. Ayman Askari has no conflicts of interest to declare. Giampiero Girolomoni declares work as a consultant and\/or speaker for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol-Meyers Squibb, Eli Lilly, LEO Pharma, Novartis, Pfizer, Samsung, Sanofi and UCB. Julio C. V. Perez-Coleman declares consulting fees from Sandoz, AbbVie and Novartis. Cristofer Salvati and Elena Bachinskaya are employees of Sandoz Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}